Last updated on July 2014

Study of NUEDEXTA in the Treatment of Pseudobulbar Affect (PBA)


Brief description of study

Study of NUEDEXTA in the Treatment of Pseudobulbar Affect (PBA)

Detailed Study Description

This is a 12-week study that will assess the safety and effectiveness of NUEDEXTA (Dextromethorphan 20mg/Quinidine10mg) in people who have Pseudobulbar Affect (PBA). PBA is a medical condition that causes sudden and involuntary bouts of crying or laughing in people with certain neurologic conditions or brain injuries. NUEDEXTA is currently FDA approved.

Clinical Study Identifier: TX138748

Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )
If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service.